Forte Biosciences
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3060 Pegasus Park Dr Bldg 6, Dallas, Tex...Phone Number
(310) 618-6994Website
www.fortebiorx.comRevenue
-Stock Symbol
FBRXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Forte Biosciences
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, a proprietary anti-CD122 monoclonal antibody targeting autoimmune diseases. FB102 inhibits IL-2/IL-15 receptor pathways regulating NK and T cells. Following positive Phase 1b celiac disease data (June 2025), Forte advanced to Phase 2 celiac trials and Phase 1b studies in vitiligo and alopecia areata, with topline data expected in 2026. No approved products; no revenue generated to date.Explore more
Forte Biosciences Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Forte Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Forte Biosciences is spiking on competitors!
Funding: Get notified immidiatlly once Forte Biosciences has new funding data
Forte Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Forte Biosciences has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Forte Biosciences
Earning: See what the market has to say on Forte Biosciences recently announced quarterly report
Click to see if Forte Biosciences had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Forte Biosciences launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Forte Biosciences
Compare insights from companies similar to Forte Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Forte Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Forte Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Forte Biosciences.
Forte Biosciences financials insights
Gather financial insights about Forte Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$25M
2024
Private Equity
$53M
Forte Biosciences Tech Stack
A closer look at the technologies used by Forte Biosciences
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Forte Biosciences has announced Phase 1b clinical trial results for FB102 in vitiligo, demonstrating a 29.6% mean VASI improvement compared with 7.9% for placebo at week 24, with statistical significance reached by day 64. Patients continued to show improvement through week 24, twelve weeks after the last dose.
Pharmaceuticals, Clinical Operations
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Forte Biosciences News & Media
The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement
Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited notable trading activity ahead of the deal, suggesting possible insider knowledge influencing price action. This case...argenx signs agreement to buy Forte Biosciences for $2.2bn
The transaction is expected to close in the third quarter of 2026.Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B
Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte...Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx
Forte Biosciences (NASDAQ:FBRX) shares climbed 39. 2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an all-cash transaction valued at approximately $2.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Forte Biosciences
Sign Up For FreeTo access detailed company insights
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, a proprietary anti-CD122 monoclonal antibody targeting autoimmune diseases. FB102 inhibits IL-2/IL-15 receptor pathways regulating NK and T cells. Following positive Phase 1b celiac disease data (June 2025), Forte advanced to Phase 2 celiac trials and Phase 1b studies... Read More
